SUMMARY Magnetic resonance imaging was performed on 50 patients with clinically definite or probable multiple sclerosis before and 15 days after starting treatment with intravenous methylprednisolone (O 5 g daily for 5 days). Scans were abnormal in 49 patients. New lesions had appeared on the second scan in nine individuals and in seven a single pre-existing lesion appeared to have become smaller but in no case were lesions seen to disappear. Two patients showed both reduction in the size of an abnormal area and development of a single new lesion indicating that corticosteroids do not appear rapidly to alter the process underlying plaque formation. Measurements of relaxation times were performed in 12 randomly selected patients. All showed elevated values in normal appearing white matter but not cortex before treatment compared with 18 healthy controls. After treatment a significant decrease of T, and T2 was observed in cortex, and of T, alone in normal appearing white matter. No significant change could be detected within lesions, a finding attributed to the wide range ofrelaxation values observed at these sites before treatment. Since brain water content is increased in normal appearing white matter of multiple sclerosis patients, and is significantly reduced by highdose methylprednisolone, resolution of oedema may contribute to the rapid spontaneous or corticosteroid induced symptomatic recovery that characterises the disease in its early stages.
Corticosteroids are widely used to treat acute exacerbations in patients with multiple sclerosis.'"3 Doubleblind controlled trials have demonstrated that corticotrophin or methylprednisolone are effective in reducing the duration ofan attack but neither influences the long term course of the disease.4" It has been suggested that resolution of oedema, characteristic of the early lesion in multiple sclerosis,6 is the main mechanism underlying early symptomatic improvement.7 The rate of recovery induced by methylprednisolone is consistent with this hypothesis; experimentally resolution ofoedema is associated with rapid restoration offunction which can occur within a few days.'
Imaging appearances consistent with blood-brain barrier (BBB) damage are often seen in acute multiple sclerosis lesions' and transient reversal of these abnormalities has been demonstrated within 8 hours of administering methylprednisolone;'°however the putative BBB abnormality may later reappear." It has been shown that corticotrophin produces reversible brain shrinkage in children with infantile spasms, suggesting a dehydrating effect of corticosteroid therapy.'2 There are thus several lines of evidence indicating that in multiple sclerosis corticosteroids might act by both reducing water content in the brain and affecting permeability of the BBB.
Proton magnetic resonance imaging (MRI) is highly sensitive in demonstrating the brain lesions in multiple sclerosis'3 and provides a method for quantifying the disease process. Affected areas can be reliably distinguished from normal appearing white matter (NAWM), cortex and cerebrospinal fluid. The relaxation times T, and T2 both positively correlate with the total amount of water and its physical state,'4 so that their measurement allows an assessment of the water content in normal and affected tissue.
Although MRI has an established role as an aid to signs although cerebrospinal fluid had previously been shown to be abnormal; MRI was normal at the time of this study. Follow-up MRI was performed a mean of 15 days after the first study. In 36 patients there was no detectable change in the scan appearances. In nine individuals a single small new lesion had appeared but in no case was this detected clinically and 7/9 of these patients had a lower DSS after methylprednisolone compared with pre-treatment scores. These lesions were seen in the cerebral (7) or cerebellar (2) hemisphere white matter. No case showed unequivocal expansion of an old lesion. In seven cases a preexisting abnormality was smaller after treatment although no lesion had disappeared. In two patients there was both a reduction in size of a pre-existing lesion, and the development of a small new one. Overall there was no correlation between these MRI changes and clinical observations in individual patients.
Relaxation times
The results of measuring T, and T2 relaxation times and their statistical analysis are given in the table. The pre-treatment values for T, and T2 in NAWM but not cortical grey matter in patients with multiple sclerosis were significantly higher than corresponding results in the healthy controls. After treatment there was a highly significant fall in the values for T, and T2 in cortex compared with pre-treatment results whereas in NAWM only the T, value was significantly reduced after treatment with methylprednisolone.
Discussion
This study demonstrates that, using high resolution imaging, there is no visible change in MRI appearance ofthe great majority ofmultiple sclerosis lesions in the cerebral hemispheres after treatment with high dose methylprednisolone. It Larsson et af' however did not find an elevation of T, though they used different field strength (I 5 T), and their long term reproducibility in phantoms (7%) was significantly worse than ours (3%). It is highly likely that this finding results from increased water content already known to be present in the brain of multiple sclerosis patients. 22 Pathological abnormalities have been described in macroscopically normal appearing white matter in the form of perivascular oedema or inflammation and astrocyte proliferation23 each of which will contribute to increased water content. The present study demonstrates that pulsed high dose intravenous methylprednisolone given to patients with multiple sclerosis significantly reduces T, in cortex and NAWM, and T2 in cortex, measured 7 days after treatment. T, is largely dependent on total water content and even small changes in this will be readily detected. Conversely, T2 is heavily influenced by the macromolecular constituents of the tissue being imaged,'4 and small changes in water content may be less easy to identify. The changes we observed in the cortex may simply reflect the fact that this part of the cerebrum normally has a much higher water content than white matter and in this respect does not differ significantly from the healthy brain.'3 But the highly significant reduction of T, and T2 in grey matter produced by methylprednisolone indicates that in patients with multiple sclerosis corticosteroids reduced water content not only in oedematous NAWM but also in previously apparently normal brain tissue.
The mode of action of corticosteroids in improving function in the central nervous system is unknown although dispersal of oedema is an obvious possibility.7"0 Our observations are consistent with this Quantitative magnetic resonance imaging in multiple sclerosis interpretation but do not preclude other or complementary effects including modification of local and systemic immunological processes2' or a direct effect on the development of demyelination.5 It is unknown whether corticosteroids have a direct effect on electrophysiological properties of partially demyelinated central axons. It is perhaps surprising that we observed no apparent change in the relaxation times in the lesions themselves; we cannot at present determine whether this reflects an alteration in the properties of the BBB in chronic lesions rendering them insusceptible to the action of corticosteroids. However, the range of values obtained within lesions is so much wider than for NAWM, probably reflecting different stages in their evolution [unpublished observation], that even a change of the same order as that seen in NAWM could not reliably be detected.
This investigation further demonstrates the dissociation between disease activity and its clinical expression in patients with multiple sclerosis. Nine new lesions appeared on MRI which were all clinically silent, and the reduction in size of other abnormal areas was not detected clinically. Although not a primary aim of the study, our observations also illustrate the therapeutic limitations of high dose intravenous methylprednisolone in patients with multiple sclerosis and show that by contrast with individuals in acute relapse, or those with progressive disease affecting the pyramidal system, patients with fixed but stable clinical deficit do not benefit usefully from this treatment; nor do corticosteroids prevent the appearance of new lesions even in the short term. This study does, however, demonstrate for the first time the value of MRI in assessing mechanisms of action of a putative new treatment for patients with multiple sclerosis and perhaps other diseases of the central nervous system. The Picker NMR machine used in this study was generously provided by the Multiple Sclerosis Society of Great Britain and Northern Ireland. JK was supported by a grant from the Schweizerische Stiftung fur medizinisch-biologische Stipendien, DHM, DGMacM and GJ by grants from the Medical Research Council.
